bioRxivImmunologyPreprint
Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells
J. J. Melenhorst, G. M. Chen, M. Wang, D. . L. Porter, P. Gao, S. Bandyopadhyay, I. Pruteanu-Malinici, C. L. Nobles, S. Maji, N. V. Frey, S. I. Gill, L. Tian, I. Kulikovskaya, M. Gupta, M. M. Davis, J. A. Fraietta, J. L. Brogdon, R. M. Young, D. E. Ambrose, A. Chew, B. L. Levine, D. L. Siegel, C. Alanio, E. J. Wherry, F. D. Bushman, , C. H. June
Abstract
The adoptive transfer of T lymphocytes reprogrammed to target tumor cells has demonstrated significant potential in various malignancies. However, little is known about the long-term potential and the clonal stability of the infused cells. Here, we studied the longest persisting CD19-redirected chimeric antigen receptor (CAR) T cells to date in two chronic lymphocytic leukemia (CLL) patients who achieved a complete remission in 2010. CAR T-cells were still detectable up to 10+ years post-infusion, with sustained remission in both patients. Surprisingly, a prominent, highly activated CD4+ population developed in both patients during the years post-infusion, dominating the CAR T-cell population at the late time points. This transition was reflected in the stabilization of the clonal make-up of CAR T-cells with a repertoire dominated by few clones. Single cell multi-omics profiling via Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) with TCR sequencing of CAR T-cells obtained 9.3 years post-infusion demonstrated that these long-persisting CD4+ CAR T-cells exhibited cytotoxic characteristics along with strong evidence of ongoing functional activation and proliferation. Our data provide novel insight into the CAR T-cell characteristics associated with long-term remission in leukemia.
- organism: human
- assay: scRNA-seq
- assay: CITE-seq
- research focus: cell type annotation
- research focus: clustering
- research focus: differential expression
- research focus: cell-cell communication
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL
Z. Bai, S. Woodhouse, … R. Fan·bioRxiv·Apr 15, 2021
- Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy
Lior Goldberg, Eric R. Haas, … Xiuli Wang·Nature CommunicationsPeer-reviewed·Feb 20, 2026
- Phytohemagglutinin-Activated CAR-T Cells: Prolonged Persistence and Enhanced Anti-Tumor Response in CD19-Specific Acute Lymphoblastic Leukemia
- Sustained antigenic engagement programs multidimensional CTL states with distinct cytotoxic capacities
Hazyadee Frecia Rodríguez-Gutiérrez, Ashwin Jainarayanan, … Roxana Khazen·bioRxiv·Oct 18, 2026
- Hallmarks of adaptive immunity in a metastatic clear cell renal cell carcinoma (ccRCC) long-term elite survivor
Felicia Tucci, Edward Drydale, … Rachael J. M. Bashford-Rogers·bioRxiv·Dec 22, 2025
- Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia
D. Sanchez Martinez, N. Tirado, … P. Menendez·bioRxiv·Mar 15, 2022